Skip to main content
Top
Published in: Molecular Cancer 1/2019

Open Access 01-12-2019 | NSCLC | Letter to the Editor

Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing

Authors: Yaxiong Zhang, Lianpeng Chang, Yunpeng Yang, Wenfeng Fang, Yanfang Guan, Aiwei Wu, Shaodong Hong, Huaqiang Zhou, Gang Chen, Xi Chen, Shen Zhao, Qiufan Zheng, Hui Pan, Lanjun Zhang, Hao Long, Haoxian Yang, Xin Wang, Zhesheng Wen, Junye Wang, Hong Yang, Xuefeng Xia, Yuanyuan Zhao, Xue Hou, Yuxiang Ma, Ting Zhou, Zhonghan Zhang, Jianhua Zhan, Yan Huang, Hongyun Zhao, Ningning Zhou, Xin Yi, Li Zhang

Published in: Molecular Cancer | Issue 1/2019

Login to get access

Abstract

Understanding of intratumor heterogeneity (ITH) among different non-small cell lung cancer (NSCLC) subtypes is necessary. Whether circulating tumor DNA (ctDNA) profile could represent these ITH is still an open question. We performed 181 multi-region tumor tissues sequencing and matched ctDNA sequencing from 32 operative NSCLC to compare ITH among different NSCLC subtypes, including EGFR-mutant lung adenocarcinoma (LUAD), KRAS-mutant LUAD, EGFR&KRAS-wild-type LUAD, and lung squamous cell carcinoma (LUSC), and examine potential value of ctDNA for ITH analysis. ITH is evaluated by ITH index (ITHi). If the somatic genetic alteration is shared by all the tissue regions, it is defined as trunk mutation. Otherwise, it is called branch mutation. The ITHi will be higher, if the tumor has less trunk mutations. We found EGFR-mutant LUAD showed significantly higher ITHi than KRAS-mutant LUAD/wild-type LUAD (P = 0.03) and numerically higher ITH than LUSC. For trunk mutations, driver mutations were identified at a higher proportion than passenger mutations (60% vs. 40%, P = 0.0023) in overall, especially in EGFR-mutant LUAD (86% vs. 14%, P = 0.0004), while it was opposite in KRAS-mutant LUAD (40% vs. 60%, P = 0.18). For branch mutations, the proportions of driver mutations and passenger mutations were similar for each NSCLC subtype. ctDNA analysis showed unsatisfactory detections of tumor-derived trunk and branch mutations (43% vs. 23%, P = 4.53e-6) among all NSCLC subtypes. In summary, EGFR-mutant LUAD has the highest ITH than other NSCLC subtypes, offering further understanding of tumorigenesis mechanisms among different NSCLC subtypes. Besides, ctDNA maybe not an appropriate method to reflect ITH.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.CrossRef
2.
go back to reference Zugazagoitia J, Molina-Pinelo S, Lopez-Rios F, et al. Biological therapies in nonsmall cell lung cancer. Eur Respir J. 2017;49:1601520. Zugazagoitia J, Molina-Pinelo S, Lopez-Rios F, et al. Biological therapies in nonsmall cell lung cancer. Eur Respir J. 2017;49:1601520.
3.
go back to reference McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168:613–28.CrossRef McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168:613–28.CrossRef
4.
go back to reference Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 2017;376:2109–21.CrossRef Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 2017;376:2109–21.CrossRef
5.
go back to reference Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32:579–86.CrossRef Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32:579–86.CrossRef
6.
go back to reference Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703–13.CrossRef Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703–13.CrossRef
7.
go back to reference Rizvi N, Hellmann M, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to pd-1 blockade in non-small cell lung cancer. Science (New York, NY). 2015;348:124–8.CrossRef Rizvi N, Hellmann M, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to pd-1 blockade in non-small cell lung cancer. Science (New York, NY). 2015;348:124–8.CrossRef
8.
go back to reference McGranahan N, Furness A, Rosenthal R, et al. Clonal neoantigens elicit t cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (New York, NY). 2016;351:1463–9.CrossRef McGranahan N, Furness A, Rosenthal R, et al. Clonal neoantigens elicit t cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (New York, NY). 2016;351:1463–9.CrossRef
9.
go back to reference Lee CK, Man J, Lord S, et al. Checkpoint inhibitors in metastatic egfr-mutated non-small cell lung cancer-a meta-analysis. J Thorac Oncol. 2017;12:403–7.CrossRef Lee CK, Man J, Lord S, et al. Checkpoint inhibitors in metastatic egfr-mutated non-small cell lung cancer-a meta-analysis. J Thorac Oncol. 2017;12:403–7.CrossRef
10.
go back to reference Garrido P, Olmedo ME, Gomez A, et al. Treating kras-mutant nsclc: latest evidence and clinical consequences. Ther Adv Med Oncol. 2017;9:589–97.CrossRef Garrido P, Olmedo ME, Gomez A, et al. Treating kras-mutant nsclc: latest evidence and clinical consequences. Ther Adv Med Oncol. 2017;9:589–97.CrossRef
Metadata
Title
Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing
Authors
Yaxiong Zhang
Lianpeng Chang
Yunpeng Yang
Wenfeng Fang
Yanfang Guan
Aiwei Wu
Shaodong Hong
Huaqiang Zhou
Gang Chen
Xi Chen
Shen Zhao
Qiufan Zheng
Hui Pan
Lanjun Zhang
Hao Long
Haoxian Yang
Xin Wang
Zhesheng Wen
Junye Wang
Hong Yang
Xuefeng Xia
Yuanyuan Zhao
Xue Hou
Yuxiang Ma
Ting Zhou
Zhonghan Zhang
Jianhua Zhan
Yan Huang
Hongyun Zhao
Ningning Zhou
Xin Yi
Li Zhang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2019
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-019-0939-9

Other articles of this Issue 1/2019

Molecular Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine